

Reference:	FOI.18370.25
Subject:	Biologic medicines in Dermatology
Date of Request:	17 September 2025

Requested:

1. How many new patients were treated for Psoriasis by the Trust's Dermatology Department in the latest 3-month period of June, July and August (or the latest 3 months available) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st of June 2025, they can be classed as a new patient for the purposes of this question.

- Adalimumab [Humira]
- Adalimumab [All Biosimilars]
- Etanercept [Enbrel]
- Etanercept [All Biosimilars]
- Infliximab [Remicade]
- Infliximab [All Biosimilars]
- Ustekinumab [Stelara]
- Ustekinumab [All Biosimilars]
- Apremilast [Otezla]
- Bimekizumab [Bimzelx]
- Brodalumab [Kyntheum]
- Certolizumab [Cimzia]
- Deucravacitinib [Sotyktu]
- Dimethyl Fumarate [Skilarence]
- Guselkumab [Tremfya]
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Secukinumab [Cosentyx]
- Spesolimab [Spevigo]
- Tildrakizumab [illumetri]

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below, the number of new Dermatology patients treated for any medical condition with the listed medications, during the period 1 June to 31 August 2025.

Medication	Number
Adalimumab [Humira]	0
Adalimumab [All Biosimilars]	*
Etanercept [Enbrel]	0
Etanercept [All Biosimilars]	0
Infliximab [Remicade]	0
Infliximab [All Biosimilars]	0
Ustekinumab [Stelara]	0

Ustekinumab [All Biosimilars]	0
Apremilast [Otezla]	0
Bimekizumab [Bimzelx]	0
Brodalumab [Kyntheum]	0
Certolizumab [Cimzia]	0
Deucravacitinib [Sotyktu]	0
Dimethyl Fumarate [Skilarence]	0
Guselkumab [Tremfya]	0
Ixekizumab [Taltz]	0
Risankizumab [Skyrizi]	0
Secukinumab [Cosentyx]	0
Spesolimab [Spevigo]	0
Tildrakizumab [illumetri]	0

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FOIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.